OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events
Study Details
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).
Protocol Summary
Time to CHD Death, Myocardial Infarction, or Urgent Coronary Revascularization, Whichever Occurs First
Timeframe: Up to approximately 6.2 years
Time to Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke, Whichever Occurs First
Timeframe: Up to approximately 6.2 years
Time to Cardiovascular Death, Myocardial Infarction, Urgent Coronary Revascularization, or Ischemic Stroke, Whichever Occurs First
Timeframe: Up to approximately 6.2 years
Percent Change From Baseline to Week 48 Lp(a) Levels
Timeframe: Baseline and Week 48
Time to Myocardial Infarction
Timeframe: Up to approximately 6.2 years
Time to CHD Death or Myocardial Infarction, Whichever Occurs First
Timeframe: Up to approximately 6.2 years
Time to Urgent Coronary Revascularization
Timeframe: Up to approximately 6.2 years
Time to Coronary Revascularization
Timeframe: Up to approximately 6.2 years
Time to CHD Death
Timeframe: Up to approximately 6.2 years
Time to Cardiovascular Death
Timeframe: Up to approximately 6.2 years
Time to Death by any Cause
Timeframe: Up to approximately 6.2 years
Time to Ischemic Stroke
Timeframe: Up to approximately 6.2 years
Serum Concentration of Olpasiran
Timeframe: Up to Week 48
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Timeframe: Up to approximately 6.2 years